Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 7/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4357817 | 0.82 | MAPT (0.58) | S1PR1SMN1; SMN2MAPTTP53RAB9A | |
| SCHEMBL3259065 | 0.78 | S1PR1 (0.49) | S1PR1SMN1; SMN2MAPTRAB9AMEN1 | |
| SCHEMBL3258918 | 0.78 | S1PR1 (0.50) | S1PR1SMN1; SMN2TP53RAB9ANPC1 | |
| SCHEMBL3257536 | 0.78 | S1PR1 (0.49) | S1PR1MAPTMEN1KMT2ATHRA | |
| SCHEMBL3258245 | 0.77 | S1PR1 (0.49) | S1PR1SMN1; SMN2MAPTTP53RAB9A | |
| SCHEMBL3260301 | 0.75 | S1PR1 (0.49) | S1PR1MAPTMEN1KMT2ATHRA | |
| SCHEMBL3257407 | 0.75 | S1PR1 (0.50) | S1PR1MAPTMEN1KMT2ATHRA | |
| SCHEMBL4518242 | 0.73 | NPC1 (0.43) | S1PR1SMN1; SMN2MAPTTP53RAB9A | |
| SCHEMBL2872160 | 0.72 | S1PR1 (0.47) | S1PR1SMN1; SMN2MAPTRAB9AMEN1 | |
| SCHEMBL3258562 | 0.72 | S1PR1 (0.44) | S1PR1SMN1; SMN2TP53RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090081636-A1 | Pharmaceutical compositions for and methods of inhibiting HCV replication | HUANG MINGJUN | 2009-03-26 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1874952-A2 | PHARMACEUTICAL COMPOSITIONS FOR AND METHODS OF INHIBITING HCV REPLICATION | Achillion Pharmaceuticals, Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006110762-A2 | PHARMACEUTICAL COMPOSITIONS FOR AND METHODS OF INHIBITING HCV REPLICATION | ACHILLION (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | RNASE1, SARS1, EIF2AK2 | S1PR1 4723/4885SMN1; SMN2 4344/4885MAPT 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.